Biote (BTMD) Moat Score: 4/10 (As of Jun. 30, 2026)


BTMD Biote Corp BTMD
66 GF Score
Price $1.74
GF Value $3.07
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biote Moat Score?

Biote BTMD +3.26% 66 Moat Score is 4 as of Jun. 30, 2026. GuruFocus rates BTMD with a GF Score™ of 66/100 and a GF Value™ of $3.07 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 678 Healthcare Providers & Services companies, Biote ranks better than 89.68% on this metric.

Biote has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Biote has Narrow Moat: Biote Corp has a discernible but modest moat due to its specialized healthcare products and some customer loyalty. However, it faces competition and lacks strong pricing power or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biote might have Narrow Moat - Discernible but modest moat.

Biote  (NAS:BTMD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biote Moat Score Related Terms

BTMD vs DCGO, PIII, EHSI: Moat Score Comparison

For the Medical Care Facilities subindustry, Biote's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biote Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's Moat Score distribution charts can be found below:

* The bar in red indicates where Biote's Moat Score falls into.


BTMD
66GF Score
Biote Corp BTMD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Biote (BTMD) has a Moat Score of 4 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Biote ranks #70 out of 678 companies in the Healthcare Providers & Services industry, placing it in the top 10.3%.
Is Biote's Moat Score too high?
Biote's current Moat Score is 4. Based on the distribution chart, Biote ranks #70 out of 678 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Biote has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Moat Score compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #70 out of 678 companies for Moat Score. This places Biote in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Biote's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $1.74 — trading 43.3% below its estimated fair value. The current Moat Score is 4. Biote's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Biote (BTMD), the current Moat Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $1.74 is trading 43.3% below its estimated GF Value™ of $3.07. GuruFocus considers Biote to be Significantly Undervalued.

Key valuation signals for BTMD:

  • Moat Score: 4
  • GF Value™: $3.07 vs. price of $1.74 (43.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
66GF Score

Get the complete analysis for BTMD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.74
Price
$3.07
GF Value